Insider Selling: Guardant Health (NASDAQ:GH) Insider Sells $7,645,056.00 in Stock

Key Points

• Guardant Health insider Terilyn Monroe sold 46,300 shares at an average price of $165.12, generating $7.65 million and reducing their direct ownership by 66.83% to 22,979 shares.
• Guardant Health shares fell 3.4% to $159.54, though the stock remains near its 52-week high of $176.58. Institutional investors own 92.6% of the company.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $183.78; 23 analysts rate the stock a Buy, one rates it a Strong Buy, and one rates it a Sell.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 46,300 shares of Guardant Health stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total value of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares in the company, valued at approximately $3,794,292.48. The trade was a 66.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Guardant Health Trading Down 3.4%

Guardant Health stock traded down $5.57 during midday trading on Thursday, hitting $159.54. The stock had a trading volume of 2,799,378 shares, compared to its average volume of 2,011,409. Guardant Health, Inc. has a 52-week low of $53.40 and a 52-week high of $176.58. The company has a market capitalization of $21.41 billion, a PE ratio of -45.71 and a beta of 1.60. The firm's fifty day moving average is $149.77 and its two-hundred day moving average is $116.59.

Wall Street Analyst Weigh In

GH has been the topic of a number of research analyst reports. Sanford C. Bernstein boosted their price target on Guardant Health from $175.00 to $200.00 and gave the stock an "outperform" rating in a report on Thursday, July 2nd. JPMorgan Chase & Co. lifted their target price on Guardant Health from $185.00 to $195.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Stephens lifted their price objective on Guardant Health from $170.00 to $195.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. Evercore restated an "outperform" rating and issued a $200.00 price target on shares of Guardant Health in a research report on Monday, July 6th. Finally, Morgan Stanley lifted their price objective on shares of Guardant Health from $175.00 to $185.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Guardant Health has a consensus rating of "Moderate Buy" and a consensus price target of $183.78.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. World Investment Advisors acquired a new stake in shares of Guardant Health in the 4th quarter worth $1,664,000. Orbimed Advisors LLC acquired a new position in Guardant Health during the 1st quarter valued at about $40,199,000. Styrax Capital LP increased its position in Guardant Health by 6.5% during the 1st quarter. Styrax Capital LP now owns 300,000 shares of the company's stock valued at $27,711,000 after buying an additional 18,411 shares in the last quarter. Caxton Associates LLP purchased a new stake in Guardant Health in the first quarter valued at about $831,000. Finally, F m Investments LLC raised its stake in Guardant Health by 24.1% in the fourth quarter. F m Investments LLC now owns 58,567 shares of the company's stock valued at $5,982,000 after buying an additional 11,363 shares during the last quarter. Institutional investors own 92.60% of the company's stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source